Missed Clinical Clues in Patients with Pheochromocytoma/paraganglioma Discovered by Imaging
Overview
Authors
Affiliations
Context: Pheochromocytomas and paragangliomas (PPGLs) are rare but potentially harmful tumors that can vary in their clinical presentation. Tumors may be found due to signs and symptoms, as part of a hereditary syndrome or following an imaging procedure.
Objective: To investigate potential differences in clinical presentation between PPGLs discovered by imaging (iPPGLs), symptomatic cases (sPPGLs) and those diagnosed during follow-up because of earlier disease/known hereditary mutations (fPPGL).
Design: Prospective study protocol, which has enrolled patients from 6 European centers with confirmed PPGLs.
Setting And Patients: Data were analyzed from 235 patients (37% iPPGLs, 36% sPPGLs, 27% fPPGLs) and compared for tumor volume, biochemical profile, mutation status, presence of metastases and self-reported symptoms.
Results: iPPGL patients were diagnosed at a significantly higher age than fPPGLs (p<0.001), found to have larger tumors (p=0.003) and higher metanephrine and normetanephrine levels at diagnosis (p=0.021). Significantly lower than in sPPGL, there was a relevant number of self-reported symptoms in iPPGL (2.9 vs. 4.3 symptoms, p<0.001). In 16.2% of iPPGL, mutations in susceptibility genes were detected, although this proportion was lower than in fPPGL (60.9%) and sPPGL (21.5%).
Conclusions: Patients with PPGLs detected by imaging were older, have higher tumor volume and more excessive hormonal secretion in comparison to those found as part of a surveillance program. Presence of typical symptoms indicates that in a relevant proportion of those patients the PPGL diagnosis had been delayed. Précis: Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic and carry a significant proportion of germline mutations in susceptibility genes.
Bechmann N, Chiapponi C, Groeben H, Grasshoff C, Zimmermann P, Walz M J Endocr Soc. 2025; 9(4):bvaf024.
PMID: 40065988 PMC: 11890919. DOI: 10.1210/jendso/bvaf024.
Raber W, Schendl R, Arikan M, Scheuba A, Mazal P, Stadlmann V Front Endocrinol (Lausanne). 2024; 15:1419028.
PMID: 39234504 PMC: 11371702. DOI: 10.3389/fendo.2024.1419028.
Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M Cancers (Basel). 2023; 15(18).
PMID: 37760633 PMC: 10526298. DOI: 10.3390/cancers15184666.
Eisenhofer G, Peitzsch M, Bechmann N, Huebner A Front Endocrinol (Lausanne). 2022; 13:901760.
PMID: 35957826 PMC: 9360409. DOI: 10.3389/fendo.2022.901760.
Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I Clin Transl Oncol. 2021; 23(10):1995-2019.
PMID: 33959901 PMC: 8390422. DOI: 10.1007/s12094-021-02622-9.